PDGFRB exhibited high expression in six tumor cell lines, including DLBC, HNSC, LIHC, PAAD, STAD, and THYM, and low expression in 12 tumor cell lines, including adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), KICH, kidney renal papillary cell carcinoma (KIRP), LUAD, LUSC, ovarian serous cystadenocarcinoma (OV), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), THCA, UCEC, and uterine carcinosarcoma (UCS) (Figure 7A). Here, PDGFRB is linked to adrenal cortex carcinoma.